CYFRA21-1、CA199、AFP联合检测对原发性肝癌的诊断价值

Clinical value of combined detection of serum CYFRA21-1,CA199 and AFP levels in patients with primary hepatic carcinoma

目的:探讨血清CYFRA21-1、CA199、AFP联合检测对原发性肝癌(PHC)的诊断价值。方法:对PHC患者65例、肝良性疾病组47例,应用电化学发光免疫分析技术检测其血清AFP、CYFRA21-1、CA199水平。结果:PHC患者血清AFP、CYFRA21-1、CA199阳性率分别为72.3%、44.6%、41.5%;AFP、CYFRA21-1、CA199联合检测阳性率显著提高,达93.8%,与单项AFP检测阳性率相比有显著性差异(P<0.05)。结论:AFP、CYFRA21-1和CA199联合检测对原发性肝癌的诊断具有良好的临床应用意义。

Objective：To explore the clinical value of combined test of serum CYFRA21 - 1, CA199, AFP levels in the diagnosis of primary hepatic carcinoma （PHC）. Methods： Technique of electrochemiluminescence immunoassay was used to measure the serum CYFRA21 - 1 ,CA199 and AFP levels in 65 patients with primary hepatic carcinoma ,47 with liver benign disease. Results： The positive rates of serum AFP, CYFRA21 - 1 and CA199 in patients with PHC were 72.3% ,44.6% and 41.5% separately. The positive rate of combined examination of serum AFP, CY- FRA21 - 1 and CA199 was 93.8% and was significantly higher than that of single AFP test（ P 〈 0. 05 ）. Conclusion： The combined examination of serum AFP,CYFRA21 -1 and CA199 is meaningful in the diagnosis of PHC.